RNA sequencing of cancer reveals novel splicing alterations

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Eswaran, Jeyanthy ^a,b,f   Horvath, Anelia ^a,b   Godbole, Sucheta ^a   Reddy, Sirigiri Divijendra ^b   Mudvari, Prakriti ^a   Ohshiro, Kazufumi ^b   Cyanam, Dinesh ^a,g   Nair, Sujit ^b   Fuqua, Suzanne A W ^c   Polyak, Kornelia ^d   Florea, Liliana D ^e   Kumar, Rakesh ^a,b  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f not available   (United Kingdom)

^g Departments of Compendia Bioscience   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; RNA; TUMOR PROTEIN;

ARTICLE; BREAST TUMOR; GENETICS; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SEQUENCE ANALYSIS;

BASE SEQUENCE; BREAST NEOPLASMS; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PROTEIN ISOFORMS; RNA, NEOPLASM; SEQUENCE ANALYSIS, RNA;

EID: 84877768911     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01689     Document Type: Article

References (54)

1. Stratton, M. R. & Wooster, R. Hereditary predisposition to breast cancer. Curr Opin Genet Dev 6, 93-97 (1996). (Pubitemid 26059058)
2. Turnbull, C. & Rahman, N. Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet 9, 321-345 (2008).
3. Robertson, L. et al. BRCA1 testing should be offered to individuals with triplenegative breast cancer diagnosed below 50 years. Br J Cancer 106, 1234-1238.
4. Wang, E. T. et al. Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470-476 (2008). (Pubitemid 352759009)
5. Eswaran, J. et al. Transcriptomic landscape of breast cancers through mRNA sequencing. Sci Rep 2, 264 (2012).
6. Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346-352.
7. Mercer, T. R. et al. Targeted RNA sequencing reveals the deep complexity of the human transcriptome. Nat Biotechnol 30, 99-104 (2012).
8. Carninci, P. et al. The transcriptional landscape of the mammalian genome. Science 309, 1559-1563 (2005).
9. Carninci, P. Taggingmammalian transcription complexity. Trends Genet 22, 501-510 (2006).
10. Strausberg, R. L. & Levy, S. Promoting transcriptome diversity. Genome Res 17, 965-968 (2007). (Pubitemid 47026343)
11. Pennisi, E. Why do humans have so few genes? Science 309, 80 (2005). (Pubitemid 40934960)
12. Johnson, J. M., Edwards, S., Shoemaker, D. & Schadt, E. E. Dark matter in the genome: evidence of widespread transcription detected by microarray tiling experiments. Trends Genet 21, 93-102 (2005). (Pubitemid 40127353)
13. Birney, E. et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 447, 799-816 (2007). (Pubitemid 46920138)
14. Grosso, A. R. et al. Tissue-specific splicing factor gene expression signatures. Nucleic Acids Res 36, 4823-4832 (2008).
15. Matlin, A. J., Clark, F. & Smith, C.W. Understanding alternative splicing: towards a cellular code. Nat Rev Mol Cell Biol 6, 386-398 (2005). (Pubitemid 40637856)
16. Heinzen, E. L. et al. Tissue-specific genetic control of splicing: implications for the study of complex traits. PLoS Biol 6, e1 (2008).
17. Lopez, A. J. Alternative splicing of pre-mRNA: developmental consequences and mechanisms of regulation. Annu Rev Genet 32, 279-305 (1998). (Pubitemid 29045315)
18. Tsunoda, T. et al. Involvement of large tenascin-C splice variants in breast cancer progression. Am J Pathol 162, 1857-1867 (2003). (Pubitemid 36613044)
19. Guttery, D. S., Shaw, J. A., Lloyd, K., Pringle, J. H. & Walker, R. A. Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev 29, 595-606.
20. Thorsen, K. et al. Alternative splicing in colon, bladder, and prostate cancer identified by exon array analysis. Mol Cell Proteomics 7, 1214-1224 (2008). (Pubitemid 352038268)
21. Shapiro, I. M. et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 7, e1002218 (2011).
22. Okumura, N., Yoshida, H., Kitagishi, Y., Nishimura, Y. & Matsuda, S. Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochem Biophys Res Commun 413, 395-399 (2011).
23. Wang, L. et al. Alternative splicing disrupts a nuclear localization signal in spleen tyrosine kinase that is required for invasion suppression in breast cancer. Cancer Res 63, 4724-4730 (2003). (Pubitemid 36951053)
24. Ghosh, A., Stewart, D. & Matlashewski, G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24, 7987-7997 (2004). (Pubitemid 39167449)
25. Lixia, M., Zhijian, C., Chao, S., Chaojiang, G. & Congyi, Z. Alternative splicing of breast cancer associated gene BRCA1 from breast cancer cell line. J Biochem Mol Biol 40, 15-21 (2007). (Pubitemid 46182730)
26. Orban, T. I. & Olah, E. Emerging roles of BRCA1 alternative splicing. Mol Pathol 56, 191-197 (2003). (Pubitemid 36981151)
27. Ng, W., Loh, A. X., Teixeira, A. S., Pereira, S. P. & Swallow, D. M. Genetic regulation of MUC1 alternative splicing in human tissues. Br J Cancer 99, 978-985 (2008).
28. Lapuk, A. et al. Exon-level microarray analyses identify alternative splicing programs in breast cancer. Mol Cancer Res 8, 961-974 (2010).
29. Dutertre, M., Vagner, S. & Auboeuf, D. Alternative splicing and breast cancer. RNA Biol 7, 403-411 (2010).
30. Ferreira, E. N. et al. Alternative splicing enriched cDNA libraries identify breast cancer-associated transcripts. BMC Genomics 11 Suppl 5, S4.
31. Brinkman, B. M. Splice variants as cancer biomarkers. Clin Biochem 37, 584-594 (2004). (Pubitemid 38845021)
32. Wu, Z. J. et al. Gene expression profiling of human breast tissue samples using SAGE-Seq. Genome Res 20, 1730-1739.
33. Trapnell, C., Pachter, L.& Salzberg, S. L. TopHat: discovering splice junctionswith RNA-Seq. Bioinformatics 25, 1105-1111 (2009).
34. Garber, M.,Grabherr, M. G.,Guttman, M. & Trapnell, C. Computational methods for transcriptome annotation and quantification using RNA-seq. Nat Methods 8, 469-477 (2011).
35. Trapnell, C. et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 7, 562-578 (2012).
36. Roberts, A., Pimentel, H., Trapnell, C. & Pachter, L. Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics 27, 2325-2329 (2011).
37. Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28, 511-515 (2010).
38. Shen, S. et al. MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data. Nucleic Acids Res 40, e61 (2012).
39. Venables, J. P. Aberrant and alternative splicing in cancer. Cancer Res 64, 7647-7654 (2004). (Pubitemid 39446889)
40. Germann, S., Gratadou, L., Dutertre, M. & Auboeuf, D. Splicing programs and cancer. J Nucleic Acids 2012, 269570.
41. Castle, J. C. et al. Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat Genet 40, 1416-1425 (2008).
42. Ewen, M. E. p53-dependent repression of cdk4 synthesis in transforming growth factor-beta-induced G1 cell cycle arrest. J Lab Clin Med 128, 355-360 (1996). (Pubitemid 27506921)
43. Miller, S. J., Suthiphongchai, T., Zambetti, G. P. & Ewen, M. E. p53 binds selectively to the 5' untranslated region of cdk4, an RNA element necessary and sufficient for transforming growth factor beta-and p53-mediated translational inhibition of cdk4. Mol Cell Biol 20, 8420-8431 (2000).
44. Nykamp, K., Lee, M. H. & Kimble, J. C. elegans La-related protein, LARP-1, localizes to germline P bodies and attenuates Ras-MAPK signaling during oogenesis. RNA 14, 1378-1389 (2008). (Pubitemid 351872194)
45. Burrows, C. et al. The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration. Nucleic Acids Res 38, 5542-5553.
46. Brognard, J., Sierecki, E., Gao, T. & Newton, A. C. PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25, 917-931 (2007). (Pubitemid 46436532)
47. Naydenov, N. G. & Ivanov, A. I. Adducins regulate remodeling of apical junctions in human epithelial cells. Mol Biol Cell 21, 3506-3517.
48. Andre, F. et al. Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis. Lancet Oncol 10, 381-390 (2009).
49. Bemmo, A. et al. Exon-level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities. PLoS One 5, e11981.
50. Dutertre, M. et al. Exon-based clustering of murine breast tumor transcriptomes reveals alternative exons whose expression is associated with metastasis. Cancer Res 70, 896-905.
51. Mercatante, D. R., Bortner, C. D., Cidlowski, J. A. & Kole, R. Modification of alternative splicing of Bcl-x pre-mRNA in prostate and breast cancer cells. analysis of apoptosis and cell death. J Biol Chem 276, 16411-16417 (2001).
52. Knudsen, E. S. et al. Progression of ductal carcinoma in situ to invasive breast cancer is associated with gene expression programs of EMT and myoepithelia. Breast Cancer Res Treat 133, 1009-1024.
53. Zhou, J., Gurates, B., Yang, S., Sebastian, S. & Bulun, S. E. Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res 61, 2328-2334 (2001). (Pubitemid 32692067)
54. Demura, M. et al. Changes in aromatase (CYP19) gene promoter usage in nonsmall cell lung cancer. Lung Cancer 73, 289-293 (2011).